AIMA
AZN icon

Ables Iannone Moore & Associates’s AstraZeneca AZN Stock Holding History

Ables Iannone Moore & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$13.5K – 93
2023
Q4 		$13.5K Buy
+100
New +$13K 0.01% 168

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ables Iannone Moore & Associates's AZN Position: Q1 2024 in Review

Ables Iannone Moore & Associates sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 100 shares — an estimated $13.5K sold.

Ables Iannone Moore & Associates first reported a position in AZN in Q4 2023 and held it in 1 quarter. The position peaked at $13.5K in Q4 2023. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

  • Ables Iannone Moore & Associates reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
  • Ables Iannone Moore & Associates sold 100 AstraZeneca shares in Q1 2024, an estimated $13.5K.
  • Ables Iannone Moore & Associates first reported a position in AstraZeneca in Q4 2023 and held it in 1 quarter.
  • Ables Iannone Moore & Associates's AstraZeneca position peaked at $13.5K in Q4 2023.
  • 1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Ables Iannone Moore & Associates's 13F filing for Q1 2024, filed 30 Apr 2024.